Media Summary: In this session, all speakers come together for a productive and informative Q&A discussion. ***No Timestamps*** Panelists: ... This session outlined ways industry can stay engaged with Submit proposed questions on this poster to DMFWorkshop2021@

Fda Usp Aam D1s4 Q - Detailed Analysis & Overview

In this session, all speakers come together for a productive and informative Q&A discussion. ***No Timestamps*** Panelists: ... This session outlined ways industry can stay engaged with Submit proposed questions on this poster to DMFWorkshop2021@ Ever wondered who's really behind the regulations you follow in pharma and medical devices? In this episode of Let's ComBinate, ... The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference. This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ...

The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference. What role do standards play in verifying the quality of a product? For medicines, dietary supplements and foods, This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ... LCDR Ramanadham from CDER's Office of Pharmaceutical Manufacturing Assessment (OPMA) reviews the goals of OPQ's ... This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ... This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

Photo Gallery

FDA-USP-AAM | D1S4 – Q&A Discussion Panel
FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions
FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy
FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process
USP Pending Monograph Process and USP compliance for Industry
Quality & Regulatory Predictability: Shaping USP Standards | Webinar co-hosted by FDA, USP, and AAM
FDA, ISO, ICH, USP, PDA - What Are These Groups and Why Do They Matter?
Resolution 1: Collaboration with the U.S. Food and Drug Administration
AGDD 2024 | D2S04 - Q&A Discussion Panel 1
AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation
AGDD 2024 | D1S05 - Q&A Discussion Panel 1
Verifying pharmaceutical quality: Standards
Sponsored
Sponsored
View Detailed Profile
FDA-USP-AAM | D1S4 – Q&A Discussion Panel

FDA-USP-AAM | D1S4 – Q&A Discussion Panel

In this session, all speakers come together for a productive and informative Q&A discussion. ***No Timestamps*** Panelists: ...

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

FDA-USP-AAM | D1S1 – FDA's Participation in USP-NF Revision Process – Challenges and Solutions

This session provided an overview of

Sponsored
FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

FDA-USP-AAM | D1S2 – Strengthening Your Compendial Strategy

This session examined the role of

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

FDA-USP-AAM | D1S3 - Industry’s Engagement in USP’s Standards-Setting Process

This session outlined ways industry can stay engaged with

USP Pending Monograph Process and USP compliance for Industry

USP Pending Monograph Process and USP compliance for Industry

Submit proposed questions on this poster to DMFWorkshop2021@

Sponsored
Quality & Regulatory Predictability: Shaping USP Standards | Webinar co-hosted by FDA, USP, and AAM

Quality & Regulatory Predictability: Shaping USP Standards | Webinar co-hosted by FDA, USP, and AAM

In December 2025, the U.S.

FDA, ISO, ICH, USP, PDA - What Are These Groups and Why Do They Matter?

FDA, ISO, ICH, USP, PDA - What Are These Groups and Why Do They Matter?

Ever wondered who's really behind the regulations you follow in pharma and medical devices? In this episode of Let's ComBinate, ...

Resolution 1: Collaboration with the U.S. Food and Drug Administration

Resolution 1: Collaboration with the U.S. Food and Drug Administration

USP

AGDD 2024 | D2S04 - Q&A Discussion Panel 1

AGDD 2024 | D2S04 - Q&A Discussion Panel 1

The first of three Q&A discussion panels from day two of the Advancing Generic Drug Development Conference.

AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation

AGDD 2024 | D1S14 - Drug-Device Combination Products – A New Methodology for Evaluation

This presentation provided key principles for comparative analyses (CA) and established understanding of essential CA ...

AGDD 2024 | D1S05 - Q&A Discussion Panel 1

AGDD 2024 | D1S05 - Q&A Discussion Panel 1

The first of four Q&A discussion panels from day one of the Advancing Generic Drug Development Conference.

Verifying pharmaceutical quality: Standards

Verifying pharmaceutical quality: Standards

What role do standards play in verifying the quality of a product? For medicines, dietary supplements and foods,

AGDD 2024 | D1S15 - Approaches to Analyzing Comparative Use Human Factors Studies

AGDD 2024 | D1S15 - Approaches to Analyzing Comparative Use Human Factors Studies

This presentation provided an overview of the current use of Comparative Use Human Factors (CUHF) studies to support various ...

Understanding FDA Inspections and Data

Understanding FDA Inspections and Data

FDA

What to Expect after an Inspection: 483s, Responses and Beyond

What to Expect after an Inspection: 483s, Responses and Beyond

During this webinar,

Application Manufacturing Assessment (4of33) Quality – Oct. 16-17, 2019

Application Manufacturing Assessment (4of33) Quality – Oct. 16-17, 2019

LCDR Ramanadham from CDER's Office of Pharmaceutical Manufacturing Assessment (OPMA) reviews the goals of OPQ's ...

AGDD 2024 | D1S10-Orally Inhaled Drug Product PSGs: General Considerations Using the Alternative...

AGDD 2024 | D1S10-Orally Inhaled Drug Product PSGs: General Considerations Using the Alternative...

This presentation recognized the significant challenges associated with conducting comparative clinical endpoint (CCEP) ...

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

FDA-NIH 2024 | D1S04 - Chemistry, Manufacturing and Controls: Regulatory Considerations and Resource

This presentation explored the essential components of Chemistry, Manufacturing, and Controls (CMC) within pharmaceutical ...

Related Video Content

U.S. Food and Drug Administration information

Apr 29, 2026 · The FDA is responsible for protecting the public health by ensuring the safety, efficacy, and security...

Food and Drug Administration - Wikipedia information

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human...

Food and Drug Administration (FDA) | USAGov information

The Food and Drug Administration (FDA) is responsible for protecting the public health by assuring the safety,...

eCFR :: Title 21 of the CFR -- Food and Drugs information

The Code of Federal Regulations (CFR) is the official legal print publication containing the codification of the...

What Is the FDA? - WebMD information

Sep 14, 2025 · What Is the FDA? The FDA – that’s the U.S. Food and Drug Administration – is part of the federal...